Home › Research › Health systems and care delivery
The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population
Brandon T. Suehs, Cralen D. Davis, Jose M. Alvir, Derek van Amerongen, Nick C. Patel PharmD, Ashish V. Joshi, Warachal Eileen Faison, Sonali N. Shah. American Journal of Alzheimer s Disease & Other Dementias®, 2013-05-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The HCRU and costs were greater for AD members during the year prior to diagnosis and during postdiagnosis years 1 and 2 compared to controls. The AD members also displayed greater comorbidity than their non-AD counterparts during postdiagnosis years 1 and 2, as measured by 2 different comorbidity indices. Members newly diagnosed with AD demonstrated greater HCRU, health care costs, and comorbidity burden compared to matched non-AD controls.
What this study adds
Evidence grade: Moderate
The record lists 3,374 participants. This study found that Medicare Advantage members newly diagnosed with Alzheimer's disease had greater health care utilization, costs, and comorbidity burden compared to matched controls without Alzheimer's disease. The higher utilization and costs were seen both before and after diagnosis.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Suehs, B. T., Davis, C. D., Alvir, J. M., van Amerongen, D., PharmD, N. C. P., Joshi, A. V., et al. (2013). The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. American Journal of Alzheimer s Disease & Other Dementias®. https://doi.org/10.1177/1533317513488911
Vancouver
Suehs BT, Davis CD, Alvir JM, van Amerongen D, PharmD NCP, Joshi AV, et al. The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population. American Journal of Alzheimer s Disease & Other Dementias®. 2013. doi:10.1177/1533317513488911. PMID: 23687180.
BibTeX
@article{suehs2013-23687180,
author = {Suehs, Brandon T. and Davis, Cralen D. and Alvir, Jose M. and van Amerongen, Derek and PharmD, Nick C. Patel and Joshi, Ashish V. and Faison, Warachal Eileen and Shah, Sonali N.},
title = {{The Clinical and Economic Burden of Newly Diagnosed Alzheimer’s Disease in a Medicare Advantage Population}},
journal = {American Journal of Alzheimer s Disease \& Other Dementias®},
year = {2013},
doi = {10.1177/1533317513488911},
pmid = {23687180},
url = {https://doi.org/10.1177/1533317513488911}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The HCRU and costs were greater for AD members during the year prior to diagnosis and during postdiagnosis years 1 and 2 compared to controls.
- The AD members also displayed greater comorbidity than their non-AD counterparts during postdiagnosis years 1 and 2, as measured by 2 different comorbidity indices.
- Members newly diagnosed with AD demonstrated greater HCRU, health care costs, and comorbidity burden compared to matched non-AD controls.
Why it matters
This study found that Medicare Advantage members newly diagnosed with Alzheimer's disease had greater health care utilization, costs, and comorbidity burden compared to matched controls without Alzheimer's disease. The higher utilization and costs were seen both before and after diagnosis.
Study details
- Study designretrospective cohort
- Participants3,374
- Evidence strengthModerate
How this study scored 54/100
Published in a peer-reviewed journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Alzheimer s Disease & Other Dementias®) |
| Journal's citation record | 1 / 4 | American Journal of Alzheimer s Disease & Other Dementias®: journal h-index 93 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A retrospective cohort study, reconstructed from past records |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,374 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 71 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.7 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 16 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Sonali N. Shah: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Pfizer (United States): institution h-index 832 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23687180) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.